1. Kung HF, Pan S, Kung MP, Billings J, Kasliwal R, Reilley J, Alavi A. In vitro and in vivo evaluation of [123J]JBZM: a potential CNS D-2 dopamine receptor imaging agent.J Nucl Med 1989; 30: 88?92.
2. Costa DC, Verhoeff NPLG, Cullum ID, Ell PJ, Syed GMS, Barrett J, Palazidou E, Toone B, Van Royen E, Bobeldijk M. In vivo characterisation of 3-iodo-6-methoxybenzamide123I in humans.Eur J Nucl Med 1990; 16: 813?816.
3. Brucke T, Podreka I, Angelberger P, Wenger S, Topitz A, Kufferle B, Muller C, Deecke L. Dopamine D2 receptor imaging with SPELT: studies in different neuropsychiatric disorders.J Cereb Blood Flow Metab 1991; 11: 220?228.
4. Kung HF, Tromposch KM, Blau M. A new brain perfusion imaging agent: N,N,N?-trimethyl-N?-(2 hydroxy-3-methyl-5-iodobenzyl)-1,3-propanediamine (HIPDM).J Nucl Med 1983; 29: 66, 72.
5. Kuhl DE, Barrio JR, Huang SC, et al. Quantifying local cerebral blood flow by N-isopropyl-p-[Jodine-123]-iodoamphetamine (IMP) tomography.J. Nucl Med 1982; 23: 196?203.